Dipòsit Digital de Documents de la UAB 4 registres trobats  La cerca s'ha fet en 0.01 segons. 
1.
9 p, 611.2 KB Adverse Reactions to Drugs of Special Interest in a Pediatric Oncohematology Service / Amaro-Hosey, Kristopher (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ; Danés Carreras, Immaculada (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Vendrell Bosch, Lourdes (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Alonso, Laura (Vall d'Hebron Institut d'Oncologia) ; Renedo-Miró, Berta (Hospital Universitari Vall d'Hebron) ; Gros, Luis (Vall d'Hebron Institut d'Oncologia) ; Vidal Guitart, Xavier (Hospital Universitari Vall d'Hebron) ; Cereza García, Gloria (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ; Agustí Escasany, M. Antònia (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Introduction: Drugs used in oncological diseases are frequently related to adverse drug reactions (ADR). Few studies have analyzed the toxicity of cancer treatments in children in real practice. Methods: An observational, longitudinal and prospective study has been carried out in an Oncohematology Service of a tertiary hospital. [...]
2021 - 10.3389/fphar.2021.670945
Frontiers in Pharmacology, Vol. 12 (may 2021)  
2.
17 p, 555.8 KB Voriconazole Use in Children : Therapeutic Drug Monitoring and Control of Inflammation as Key Points for Optimal Treatment / Valle-T-Figueras, José María (Institut d'Investigació Biomèdica Sant Pau) ; Renedo-Miró, Berta (Hospital Universitari Vall d'Hebron) ; Benítez Carabante, Maria Isabel (Hospital Universitari Vall d'Hebron) ; Díaz de Heredia, Cristina (Hospital Universitari Vall d'Hebron) ; Vima Bofarull, Jaume (Hospital Universitari Vall d'Hebron) ; Mendoza-Palomar, Natalia Ana (Hospital Universitari Vall d'Hebron) ; Martin-Gomez, M. Teresa (Hospital Universitari Vall d'Hebron) ; Soler-Palacín, Pere (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona
Voriconazole plasma concentrations (PC) are highly variable, particularly in children. Dose recommendations in 2-12-year-old patients changed in 2012. Little data on therapeutic drug monitoring (TDM) after these new recommendations are available. [...]
2021 - 10.3390/jof7060456
Journal of Fungi, Vol. 7 (june 2021)  
3.
7 p, 501.1 KB Antifungal stewardship in a tertiary care paediatric hospital : the PROAFUNGI study / Mendoza-Palomar, Natalia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Garcia-Palop, Beatriz (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Melendo, Susana (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Martín, Maria Teresa (Hospital Universitari Vall d'Hebron) ; Renedo-Miró, Berta (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Soler-Palacín, Pere (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Fernández-Polo, Aurora (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Universitat Autònoma de Barcelona
The increasing use of antifungal drugs (AF) in children and the concern for related adverse events and costs has led to the development of specific AF stewardship programmes (AFS). Studies in adult patients have shown improvements in AF prescription and usage after implementation, but paediatric data are scant. [...]
2021 - 10.1186/s12879-021-05774-9
BMC Infectious diseases, Vol. 21 (january 2021)  
4.
9 p, 567.0 KB Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers : a randomized study / Espinel Garuz, Eugenia (Hospital Universitari Vall d'Hebron) ; Joven Maried, Jorge (Universitat Rovira i Virgili) ; Gil, Iván (Hospital Universitari Vall d'Hebron) ; Suñé, Pilar (Hospital Universitari Vall d'Hebron) ; Renedo-Miró, Berta (Hospital Universitari Vall d'Hebron) ; Fort Ros, Joan (Hospital Universitari Vall d'Hebron) ; Serón Micas, Daniel (Hospital Universitari Vall d'Hebron)
Background: Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are renoprotective but both may increase serum potassium concentrations in patients with chronic kidney disease (CKD). [...]
2013 - 10.1186/1756-0500-6-306
BMC public health, Vol. 6, N. 306 (August 2013) , p. 1-9  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.